The estimated Net Worth of Advisors Llc Orbi Med Capit... is at least $53.9 Milion dollars as of 11 May 2016. Advisors Capit owns over 250,000 units of Intellia Therapeutics Inc stock worth over $53,882,523 and over the last 8 years Advisors sold NTLA stock worth over $0.
Advisors has made over 1 trades of the Intellia Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Advisors bought 250,000 units of NTLA stock worth $4,500,000 on 11 May 2016.
The largest trade Advisors's ever made was buying 250,000 units of Intellia Therapeutics Inc stock on 11 May 2016 worth over $4,500,000. On average, Advisors trades about 250,000 units every 0 days since 2016. As of 11 May 2016 Advisors still owns at least 2,662,180 units of Intellia Therapeutics Inc stock.
You can see the complete history of Advisors Capit stock trades at the bottom of the page.
Over the last 8 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela a Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: